Today, Vertex Pharmaceuticals Inc. released the initial Phase 3 clinical trial data for one of two next-generation, triple-combination modulators currently being tested.
Site Search
Showing 1 - 10 of 56 results
News
|
|
1 min read
News
|
|
2 min read
News
|
|
3 min read
News
|
|
2 min read
A new drug intended to make it easier to clear mucus from the lungs of people with cystic fibrosis showed promising results in a Phase 2 clinical trial. The drug, called SPX-101, blocks the overactive sodium channels that line CF lung cells.
News
|
|
2 min read
News
|
|
2 min read
New data show positive results in individuals with a single F508del mutation as well as people with two copies of F508del and support continued development of triple combination therapies.
News
|
|
6 min read
News
|
|
1 min read
The New England Journal of Medicine, the world's most influential and widely read medical periodical, features a study this week about a Phase 2 clinical trial of VX-770, an oral drug in development that targets the root cause of cystic fibrosis.
News
|
|
3 min read
News
|
|
1 min read